Insecticides India Reports Q3FY26 Results, Declares ₹2 Interim Dividend
Insecticides India delivered resilient Q3FY26 performance with 8% growth amid industry challenges, driven by new product launches like SPARCLE and strategic market engagement. The company declared ₹2 interim dividend and outlined growth revival roadmap targeting 8-10% sustainable growth over next 2-3 years through capacity expansion and premiumization strategy.

*this image is generated using AI for illustrative purposes only.
Insecticides (India) Limited has announced its unaudited financial results for the third quarter ended December 31, 2025, alongside declaring an interim dividend for shareholders. The agro-chemicals manufacturer's Board of Directors approved the results at their meeting held on January 30, 2026, followed by an earnings conference call to discuss performance and strategy.
Q3FY26 Financial Performance
The company's standalone performance for Q3FY26 showed mixed results compared to the previous year. Revenue from operations reached ₹38,356.38 lacs, representing a 6.78% increase from ₹35,922.71 lacs in Q3FY24. However, net profit declined to ₹884.30 lacs from ₹1,500.14 lacs in the corresponding quarter last year.
| Metric: | Q3FY26 | Q3FY25 | Q3FY24 |
|---|---|---|---|
| Revenue from Operations: | ₹38,356.38 lacs | ₹64,124.89 lacs | ₹35,922.71 lacs |
| Net Profit: | ₹884.30 lacs | ₹5,531.02 lacs | ₹1,500.14 lacs |
| Basic EPS: | ₹3.04 | ₹19.01 | ₹5.15 |
| Total Income: | ₹38,445.26 lacs | ₹64,392.33 lacs | ₹35,943.63 lacs |
Nine Months Performance
For the nine months ended December 31, 2025, the company demonstrated resilient performance with revenue from operations of ₹1,71,618.51 lacs compared to ₹1,64,312.07 lacs in the corresponding period last year. Net profit for the nine-month period stood at ₹12,145.37 lacs versus ₹12,574.07 lacs in the previous year.
| Parameter: | 9M FY26 | 9M FY25 |
|---|---|---|
| Revenue Growth: | 4.45% | - |
| Nine-month EPS: | ₹41.74 | ₹42.71 |
| Total Expenses: | ₹1,56,021.88 lacs | ₹1,47,937.75 lacs |
Management Commentary and Strategic Outlook
During the earnings conference call, Managing Director Rajesh Kumar Aggarwal highlighted that Q3 was marked by challenging operating conditions including weak farmer activities, cautious channel behavior, weather issues, and low pest incidence. Despite these headwinds, the company delivered 8% growth driven by proactive market engagement and strategic business decisions.
| Business Segment Performance: | 9M FY26 Contribution |
|---|---|
| B2C Segment: | 76% |
| B2B Segment: | 20% |
| Exports: | 4% |
| Premium Products (within B2C): | 59% |
| Generic Products (within B2C): | 41% |
The management emphasized that growth during the quarter was volume-led rather than value-led, with B2B segment showing approximately 15% growth while B2C segment grew by 3-4%. The company faced sales returns of ₹50.00 crores in Q3, bringing total goods returns to approximately ₹200.00 crores for the year.
New Product Launches and Innovation
A key positive development was the strong traction from new product launches. SPARCLE, a broad-spectrum insecticide for brown planthopper control in rice, was successfully launched using advanced chemistry from Corteva. Other recent launches including Centran and Million also witnessed encouraging farmer response. The company launched 5 new products during the first 9 months and plans to launch another 5 products in the upcoming kharif season.
Interim Dividend Declaration
The Board declared an interim dividend of ₹2.00 per equity share, representing 20% on the face value of ₹10 per share for financial year 2025-26.
| Dividend Details: | Information |
|---|---|
| Dividend Amount: | ₹2.00 per share |
| Record Date: | February 6, 2026 |
| Payment Date: | On or after February 11, 2026 |
| Face Value: | ₹10 per share |
Future Outlook and Strategic Initiatives
The management expects Q4 to remain challenging with continued margin pressure due to higher base of last year. However, they outlined a clear growth revival roadmap targeting 8-10% sustainable growth over the next 2-3 years. Key strategic initiatives include capacity expansion at Dahej (expected operational by end of fiscal) and Sotanala formulation activities starting in next kharif season.
The company continues to focus on premiumization with 180-plus registrations across 22 countries for export growth. International subsidiary Kaeros achieved sales of approximately ₹90.00 crores in 9 months, on track to touch ₹100.00 crores for the full year.
Source: Earnings Conference Call Transcript
Historical Stock Returns for Insecticides
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.24% | -2.33% | +1.40% | -23.18% | +3.66% | +102.64% |


































